HDAC2 and skin basal cell carcinoma: Together with high level expression of HDAC1 and HDAC2 in human BCC samples (Supporting Information, Fig. 8), our findings therefore warrant further studies of 4SC‐202 and other class I HDACi as combination or second‐line drugs to tackle the problem of frequent SMOi‐resistance development observed in HH‐driven cancers such as BCC.